Chester County News and Community Website
BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced its plans to explore utilizing Molecular Envelope Technology (MET) for the intranasal delivery of a mRNA COVID vaccine. This innovative direction …
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced that findings from its dose range toxicity study for NES100, an innovative intranasal peptide for managing acute and chronic non-cancer pain, …
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has commended Nanomerics for the successful completion of a human study utilizing its proprietary Molecular Envelope Technology (MET). The Phase I SUNLIGHT trial …
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced the successful completion of a full study on its localized pain management product, Probudur™, conducted in partnership with the U.S. Army …
Virpax Pharmaceuticals Advances Pain Management with Promising Probudur Study Results Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced that Matthew Barnes, the company’s senior director of portfolio management, will be presenting at the Outsourcing in Clinical Trials (OCT) Conference. …
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference Read More